) has been revised to $7.14 / share. This is an increase of 12.00% from the prior estimate of $6.38 dated April 12, 2026. The price target is an average of many targets provided by analysts. The ...
Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results